Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.
作者信息
Meier-Abt Fabienne, Wolski Witold E, Tan Ge, Kummer Sandra, Amon Sabine, Manz Markus G, Aebersold Ruedi, Theocharides Alexandre P A
机构信息
Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
出版信息
Blood Cancer J. 2021 Feb 11;11(2):31. doi: 10.1038/s41408-021-00423-5.
Abstract
摘要
相似文献
1
Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.
Blood Cancer J. 2021 Feb 11;11(2):31. doi: 10.1038/s41408-021-00423-5.
2
Differential expression of hydroxyurea transporters in normal and polycythemia vera hematopoietic stem and progenitor cell subpopulations.
Exp Hematol. 2021 May;97:47-56.e5. doi: 10.1016/j.exphem.2021.02.011. Epub 2021 Mar 4.
3
From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.
Semin Hematol. 1997 Jan;34(1):17-23.
4
Circulating hematopoietic progenitor cells in polycythemia vera: the in vivo effect of hydroxyurea.
Ann Hematol. 1995 Sep;71(3):119-21. doi: 10.1007/BF01702646.
5
Management of polycythemia vera with hydroxyurea.
Semin Hematol. 1997 Jan;34(1):24-8.
6
[Treatment with hydroxyurea of polycythemia vera in a 11 year-old child].
Arch Pediatr. 1996 Sep;3(9):870-3. doi: 10.1016/0929-693x(96)87575-0.
7
Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
Am J Clin Oncol. 1998 Feb;21(1):105-6. doi: 10.1097/00000421-199802000-00024.
8
High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4.
J Biol Chem. 1995 Oct 6;270(40):23282-92. doi: 10.1074/jbc.270.40.23282.
9
[Hydroxyurea induced-leg ulcer in polycythemia vera].
Tunis Med. 2011 Mar;89(3):292-4.
10
Epstein-Barr virus-positive mucocutaneous ulcer in a patient with polycythemia vera treated with oral hydroxyurea.
J Dermatol. 2018 Apr;45(4):e82-e83. doi: 10.1111/1346-8138.14127. Epub 2017 Nov 15.
引用本文的文献
1
New insights into the generation and function of megakaryocytes in health and disease.
Haematologica. 2025 Jul 1;110(7):1500-1512. doi: 10.3324/haematol.2024.287236. Epub 2025 Mar 27.
2
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.
Leukemia. 2024 Sep;38(9):1971-1984. doi: 10.1038/s41375-024-02354-z. Epub 2024 Jul 18.
3
Serglycin controls megakaryocyte retention of platelet factor 4 and influences megakaryocyte fate in bone marrow.
Blood Adv. 2025 Jan 14;9(1):15-28. doi: 10.1182/bloodadvances.2024012995.
4
Identification of hub genes and potential molecular mechanisms related to drug sensitivity in acute myeloid leukemia based on machine learning.
Front Pharmacol. 2024 Apr 8;15:1359832. doi: 10.3389/fphar.2024.1359832. eCollection 2024.
5
: A Comprehensive -Package for Proteomics Differential Expression Analysis.
J Proteome Res. 2023 Apr 7;22(4):1092-1104. doi: 10.1021/acs.jproteome.2c00441. Epub 2023 Mar 20.
6
Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.
Blood Adv. 2022 Jun 14;6(11):3480-3493. doi: 10.1182/bloodadvances.2021005344.
本文引用的文献
1
Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.
Blood. 2020 Oct 29;136(18):2051-2064. doi: 10.1182/blood.2019004095.
2
Benchmark and integration of resources for the estimation of human transcription factor activities.
Genome Res. 2019 Aug;29(8):1363-1375. doi: 10.1101/gr.240663.118. Epub 2019 Jul 24.
3
Sensitive Quantitative Proteomics of Human Hematopoietic Stem and Progenitor Cells by Data-independent Acquisition Mass Spectrometry.
Mol Cell Proteomics. 2019 Jul;18(7):1454-1467. doi: 10.1074/mcp.TIR119.001431. Epub 2019 Apr 11.
4
Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer.
Cancer Lett. 2019 Feb 28;443:1-12. doi: 10.1016/j.canlet.2018.11.017. Epub 2018 Nov 24.
5
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Am J Hematol. 2019 Jan;94(1):133-143. doi: 10.1002/ajh.25303. Epub 2018 Nov 9.
6
Myeloproliferative neoplasm stem cells.
Blood. 2017 Mar 23;129(12):1607-1616. doi: 10.1182/blood-2016-10-696005. Epub 2017 Feb 3.
7
TGF-β signaling in the control of hematopoietic stem cells.
Blood. 2015 Jun 4;125(23):3542-50. doi: 10.1182/blood-2014-12-618090. Epub 2015 Apr 1.
8
Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion.
Nat Med. 2014 Nov;20(11):1315-20. doi: 10.1038/nm.3707. Epub 2014 Oct 19.
9
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
J Exp Med. 2014 Oct 20;211(11):2213-30. doi: 10.1084/jem.20131371. Epub 2014 Oct 6.
10
Molecular regulation of stem cell quiescence.
Nat Rev Mol Cell Biol. 2013 Jun;14(6):329-40. doi: 10.1038/nrm3591.
Zotero 插件